104472-62-0

Upstream product

• 35621-01-3 4-aminopiperidine dihydrochloride 
• 208398-29-2 2-chloro-1-(tetrahydropyran-2-yl)-1H-benzimidazole 
• 73734-07-3 (1H-benzimidazol-2-yl)-(1-ethoxycarbonyl-piperidin-4-yl)amine 
• 4857-06-1 2-chloro-1H-benzoimidazole 
• 95-54-5 1,2-diamino-benzene 
• 615-16-7 1,3-dihydro-2H-benzimidazol-2-one 
• 191604-53-2 1,1-dimethylethyl 4-(1H-benzimidazol-2-ylamino)-1-piperidinecarboxylate 
• 58859-46-4 ethyl 4-aminopiperidine-1-carboxylate 

Downstream Products

• 247035-02-5 ethyl 4-{4-(1H-benzimidazol-2-ylamino)piperidin-1-yl}benzoate 
• 247035-03-6 4-{4-(1H-benzimidazol-2-ylamino)piperidin-1-yl}benzoic acid 
• 247033-91-6 tert-butyl (2S)-amino-3-[4-[4-{(1-tert-butoxycarbonyl-1H-benzimidazol-2-yl)amino}piperidin-1-yl]benzoylamino]propionate 
• 247033-71-2 tert-butyl (2S)-benzenesulfonylamino-3-[4-{4-(1H-benzimidazol-2-ylamino)piperidin-1-yl}benzoylamino]propionate 
• 247033-88-1 3-{4-[4-(1H-benzoimidazol-2-ylamino)-piperidin-1-yl]-benzoylamino}-2-benzyloxycarbonylamino-propionic acid tert-butyl ester 
• 247034-00-0 3-{4-[4-(1H-benzoimidazol-2-ylamino)-piperidin-1-yl]-benzoylamino}-2-(4-nitro-benzenesulfonylamino)-propionic acid 
• 247033-92-7 tert-butyl (2S)-(butane-1-sulfonyl)amino-3-[4-[4-{(1-tert-butoxycarbonyl-1H-benzimidazol-2-yl)amino}piperidin-1-yl]benzoylamino]propionate 
• 247033-90-5 tert-butyl (2S)-benzyloxycarbonylamino-3-[4-[4-{(1-tert-butoxycarbonyl-1H-benzimidazol-2-yl)amino}piperidin-1-yl]benzoylamino]propionate 
• 247033-97-2 2-(1-{4-[2-tert-butoxycarbonyl-2-(4-fluoro-benzenesulfonylamino)-ethylcarbamoyl]-phenyl}-piperidin-4-ylamino)-benzoimidazole-1-carboxylic acid tert-butyl ester 
• 247033-99-4 2-(1-{4-[2-tert-butoxycarbonyl-2-(4-nitro-benzenesulfonylamino)-ethylcarbamoyl]-phenyl}-piperidin-4-ylamino)-benzoimidazole-1-carboxylic acid tert-butyl ester 
• 247033-95-0 2-(1-{4-[2-tert-butoxycarbonyl-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-phenyl}-piperidin-4-ylamino)-benzoimidazole-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Remarkably selective palladium-catalyzed amination process: Rapid assembly of multiamino based structures

Palladium-catalyzed selective amination by a primary amine in the presence of a secondary amine provided up to >99:1 selectivity with high yields.

Structure-Activity Relationship Studies Reveal New Astemizole Analogues Active against Plasmodium falciparum in Vitro

In the context of drug repositioning and expanding the existing structure-activity relationship around astemizole (AST), a new series of analogues were designed, synthesized, and evaluated for their antiplasmodium activity. Among 46 analogues tested, compounds 21, 30, and 33 displayed high activities against asexual blood stage parasites (PfNF54 IC50 = 0.025-0.043 μM), whereas amide compound 46 additionally showed activity against late-stage gametocytes (stage IV/V; PfLG IC50 = 0.6 ± 0.1 μM) and 860-fold higher selectivity over hERG (46, SI = 43) compared to AST. Several analogues displaying high solubility (Sol > 100 μM) and low cytoxicity in the Chinese hamster ovary (SI > 148) cell line have also been identified.

From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis

Human African trypanosomiasis is a neglected tropical disease that is lethal if left untreated. Existing therapeutics have limited efficacy and severe associated toxicities. 2-(2-(((3-((1H-Benzo[d]imidazol-2-yl)amino)propyl)amino)methyl)-4,6-dichloro-1H-indol-1-yl)ethan-1-ol (NEU-1053) has recently been identified from a high-throughput screen of >42,000 compounds as a highly potent and fast-acting trypanocidal agent capable of curing a bloodstream infection of Trypanosoma brucei in mice. We have designed a library of analogues to probe the structure-activity relationship and improve the predicted central nervous system (CNS) exposure of NEU-1053. We report the activity of these inhibitors of T. brucei, the efficacy of NEU-1053 in a murine CNS model of infection, and identification of the target of NEU-1053 via X-ray crystallography.

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 2: Synthesis of potent αvβ3/αIIbβ3 dual antagonists

We synthesized 4-aminopiperidine derivatives of our prototype integrin αvβ3 antagonist 1 in an attempt to increase the activity and water solubility. Introduction of one or two hydrophilic moieties into the central aromatic ring and/or the benzene ring at the C-terminus of 1 increased water solubility and enhanced inhibition of cell adhesion. The results of a structure-activity relationships (SAR) study indicated that the torsion angle between the central aromatic ring and the piperidine ring, and the acidity at the sulfonamide moiety, might be important for αvβ 3 receptor binding activity. Some of these compounds are novel and potent αvβ3/αIIbβ 3 dual antagonists with acceptable water solubility and a satisfactory early absorption, distribution, metabolism, excretion, and toxicity (ADMET) profile.

Aminopiperidine derivates as integrin αvβ3 antagonists

An objective of the present invention is to provide compounds having integrin αvβ3antagonistic activity, cell adhesion inhibitory activity, GP IIb/IIIa antagonistic activity, and/or human platelet aggregation inhibitory activity, and, therapeutic agents for treating cardiovascular diseases, angiogenesis-related diseases, cerebrovascular diseases and the like and for inhibiting platelet aggregation. The derivatives according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein A represents a five- to seven-membered heterocyclic group containing two nitrogen atoms or the like; D represents >NH2, >CH2or the like; X and Z represent CH or a nitrogen atom; R7and R8represent alkyl, halogen or the like; Q represents >C═O, >CH2or the like; R9represents H, alkyl, aralkyl or the like; R10represents H, alkynyl or the like; R11represents H, substituted amino or the like; R12represents H or alkyl; m is 0 to 5; n is 0 to 4; p and q are each 1 to 3; and r is 0 or 1.